<DOC>
	<DOCNO>NCT00829309</DOCNO>
	<brief_summary>This study compare relative bioavailability ( rate extent absorption ) Pravastatin Sodium Tablets 80 mg Teva Pharmaceutical Industries , Ltd. PravacholÂ® Tablets 80 mg Bristol-Myers Squibb Company follow single oral dose ( 1 x 80 mg tablet ) healthy adult male subject administer non-fasting condition .</brief_summary>
	<brief_title>Pravastatin 80 mg Tablets Dosed Healthy Subjects Under Non-Fasting Conditions</brief_title>
	<detailed_description>Detailed Description Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method Outcome : Confidence interval fell within 80-125 % therefore meet FDA Bioequivalence criterion ; drug relate , serious , unexpected adverse event report study .</detailed_description>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>Inclusion Criteria Screening Demographics : All subject select study healthy men 18 year age old time dose . The subject 's body mass index ( BMI ) less equal 30 . Screening Procedures : Each subject complete screening process within 28 day prior period I dose . Consent document screen evaluation HIV antibody determination review , discuss sign potential participant full implementation screening procedure . Screening include general observation , physical examination , demographic , medical medication history , electrocardiogram , sit blood pressure heart rate , respiratory rate temperature . The physical examination include , may limit , evaluation cardiovascular , gastrointestinal , respiratory central nervous system . The screen clinical laboratory procedure include : HEMATOLOGY : hematocrit , hemoglobin , WBC count differential , RBC count , platelet count CLINICAL CHEMISTRY : serum creatinine , BUN , glucose , AST ( GOT ) , ALT ( GPT ) , albumin , total bilirubin , total protein , alkaline phosphatase HIV antibody , hepatitis GB surface antigen , hepatitis C antibody screen URINALYSIS : dipstick ; full microscopic examination dipstick positive URINE DRUG SCREEN : ethyl alcohol , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine metabolite , opiates phencyclidine Exclusion Criteria Subjects recent history drug alcohol addiction abuse . Subjects presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined clinical investigator ) . Subjects whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . Subjects demonstrate reactive screen hepatitis B surface antigen , hepatitis C antibody HIV antibody . Subjects demonstrate positive drug abuse screen screen study . Subjects history allergic response ( ) pravastatin relate drug . Subjects history clinically significant allergy include drug allergy . Subjects clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) . Subjects currently report use tobacco product within 90 day Period I dose administration . Subjects take drug know induce inhibit hepatic drug metabolism 28 day prior Period I dose . Subjects report donate great 150 mL blood within 28 day prior Period I dose . All subject advise donate blood four week complete study . Subjects donate plasma ( e.g . plasmapheresis ) within 14 day prior Period I dose . All subject advise donate plasma four week complete study . Subjects report receive investigational drug within 28 day prior Period I dose . Subjects report take systemic prescription medication 14 day prior Period I dose . Subjects report intolerance direct venipuncture . Subjects report consume abnormal diet 28 day prior Period I dose .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>